A COMPARATIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF TOPICAL CIPROFLOXACIN V/S FORTIFIED GENTAMICIN-CEFTAZIDIME IN BACTERIAL KERATITIS” AT A TERTIARY CARE CENTRE IN TELANGANA

N. KARUNASREE; FAHEEM BEGUM; MOHAMMED OBAIDULLAH KHAN; KHATIJATUL KUBRA NAMEERA

doi:10.22159/ijpps.2024v16i3.49807

Authors

N. KARUNASREE Department of Pharmacology, Osmania Medical College, Osmania Medical College, 5-1-876, Turrebaz Khan Rd, Troop Bazaar, Koti, Hyderabad-500095, Telangana, India https://orcid.org/0000-0001-6412-1213
FAHEEM BEGUM Department of Pharmacology, Osmania Medical College, Osmania Medical College, 5-1-876, Turrebaz Khan Rd, Troop Bazaar, Koti, Hyderabad-500095, Telangana, India https://orcid.org/0009-0006-5049-6595
MOHAMMED OBAIDULLAH KHAN Department of Ophthalmology, Osmania Medical College, 5-1-876, Turrebaz Khan Rd, Troop Bazaar, Koti, Hyderabad-500095, Telangana, India https://orcid.org/0000-0003-3448-0033
KHATIJATUL KUBRA NAMEERA Department of Pharmacology, Osmania Medical College, 5-1-876, Turrebaz Khan Rd, Troop Bazaar, Koti, Hyderabad-500095, Telangana, India

DOI:

https://doi.org/10.22159/ijpps.2024v16i3.49807

Keywords:

Ceftazidime, Gentamicin, Fortified, Ciprofloxacin, Bacterial keratitis

Abstract

Objective: To compare the efficacy and safety of topical ciprofloxacin v/s fortified gentamicin-ceftazidime in bacterial keratitis.

Methods: This was a randomized control trial done on 60 subjects with 30 subjects in each group. The clinical signs and symptoms are recorded in two groups of bacterial keratitis patients at baseline and after 2 w of treatment using ciprofloxacin ophthalmic solution and standard therapy regimen of fortified gentamicin-ceftazidime using scoring of ocular signs and symptoms (1=minimum, not present), (5=maximum, severe) with a study period of 3 mo

Results: The group administered with fortified ceftazidime+gentamicin demonstrated superior clinical and statistical efficacy compared to ciprofloxacin in treating bacterial keratitis. This regimen led to a substantial alleviation of symptoms and minimized ocular discomfort to a greater extent. Notably, the calculated p-value for the day 14 score, standing at 0.02 (below the 0.05 threshold), underscores the significant superiority of fortified ceftazidime+gentamicin in symptom reduction.

Conclusion: We conclude that fortified ceftazidime+gentamicin is better than ciprofloxacin for the treatment of bacterial keratitis.

Downloads

Download data is not yet available.

References

Garg P, Krishna PV, Stratis AK, Gopinathan U. The value of corneal transplantation in reducing blindness. Eye (Lond). 2005;19(10):1106-14. doi: 10.1038/sj.eye.6701968, PMID 16304591.

World Health Organization. Blindness and visual impairment; 2018.

Upadhyay MP, Karmacharya PC, Koirala S, Tuladhar NR, Bryan LE, Smolin G. Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am J Ophthalmol. 1991;111(1):92-9. doi: 10.1016/s0002-9394(14)76903-x, PMID 1985498.

Gonzales CA, Srinivasan M, Whitcher JP, Smolin G. Incidence of corneal ulceration in Madurai district, South India. Ophthalmic Epidemiol. 1996;3(3):159-66. doi: 10.3109/09286589609080122, PMID 8956320.

Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79(3):214-21. PMID 11285665.

Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Available data on blindness (update 1994). Ophthalmic Epidemiol. 1995;2(1):5-39. doi: 10.3109/09286589509071448, PMID 7585234.

Erie JC, Nevitt MP, Hodge DO, Ballard DJ. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. Arch Ophthalmol. 1993;111(12):1665-71. doi: 10.1001/archopht.1993.01090120087027, PMID 8155038.

Upadhyay MP, Karmacharya PC, Koirala S, Shah DN, Shakya S, Shrestha JK. The Bhaktapur eye study: ocular trauma and antibiotic prophylaxis for the prevention of corneal ulceration in Nepal. Br J Ophthalmol. 2001;85(4):388-92. doi: 10.1136/bjo.85.4.388, PMID 11264124.

Lim AS. Mass blindness has shifted from infection (onchocerciasis, trachoma, corneal ulcers) to cataract. Ophthalmologica. 1997;211(4):270. doi: 10.1159/000310806, PMID 9216023.

Report of national programme for control of blindness. India and World Health Organization; 1986-89.

O’Brien Kieran Kieran S, Lietman TM, Keenan JD, Whitcher JP. Microbial keratitis: a community eye health approach. Community Eye Health. 2015;28(89):1-2. PMID 26435582.

Austin A, Lietman T, Rose Nussbaumer J. Update on the management of infectious keratitis. Ophthalmology. 2017 Nov;124(11):1678-89. doi: 10.1016/j.ophtha.2017.05.012, PMID 28942073.

Parmar P, Salman A, Kalavathy CM, Kaliamurthy J, Prasanth DA, Thomas PA. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol. 2006 Feb;141(2):282-6. doi: 10.1016/j.ajo.2005.08.081, PMID 16458681.

Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin bacterial keratitis study group. Ophthalmology. 1996 Nov;103(11):1854-62. doi: 10.1016/s0161-6420(96)30416-8, PMID 8942881.